STO-CSCO Joint Symposium 2017

Continuing to build on the vibrant partnership of STO and CSCO, this symposium will be featured during the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) from September 26 – 30, 2017.

Translated Articles

《肿瘤学家》精选论文
Read translations of selected articles targeting practice issues relevant to Chinese clinicians.

Browse All Topics

The Oncologist Clinical Trial Results

《肿瘤学家》中国项目概览
Download a 2-page pdf overview of The Oncologist’s Clinical Trial Results section information.

Video Library

视频库
Watch the latest presentations from the STO First Advisory Council: LUNG CANCER: A Grand Challenge for Public Health & Education.

Past Meetings

Welcome to 'The Oncologist' in China

Recent Translated Articles from The Oncologist

Volume 22, Number 8, August 2017


Clinical Trial Results

培美曲塞延时输注联合吉西他滨治疗难治性转移性结直肠癌:临床前依据和II期研究结果
Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results
Alessandro Passardi, Francesca Fanini, Livia Turci, Flavia Foca, Paola Rosetti, Silvia Ruscelli, Andrea Casadei Gardini, Martina Valgiusti, Claudio Dazzi, Maurizio Marangolo
The Oncologist 2017; 22:886-e79; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0206

在晚期肾细胞癌受试者中联合使用贝伐珠单抗与伊沙匹隆的一项II期、多中心研究
A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
Mauricio Burotto, Maureen Edgerly, Margarita Velarde, Sanjeeve Balasubramaniam, Harry Drabkin, Juan G. Gormaz, Ciara O'Sullivan, Ravi Madan, Tito Fojo
The Oncologist 2017; 22:888-e84; first published on July 5, 2017; doi:10.1634/theoncologist.2017-0211

Breast Cancer

通过关联研究在中国汉族女性中确认了3个与乳腺癌特异性分子亚型相关的易感基因位点
Association Study Confirmed Three Breast Cancer‐Specific Molecular Subtype‐Associated Susceptibility Loci in Chinese Han Women
Yihui Xu, Mengyun Chen, Chenchen Liu, Xiaowei Zhang, Wei Li, Huaidong Cheng, Jun Zhu, Mingjun Zhang, Zhendong Chen, Bo Zhang
The Oncologist 2017; 22:890-894; first published on April 13, 2017; doi:10.1634/theoncologist.2016-0423

HER2阳性转移性乳腺癌患者在既往曲妥珠单抗辅助治疗后接受一线HER2靶向姑息治疗时疗效下降
First‐Line Palliative HER2‐Targeted Therapy in HER2‐Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab‐Based Therapy
Hánah N. Rier, Mark‐David Levin, Joost van Rosmalen, Monique M. E. M. Bos, Jan C. Drooger, Paul de Jong, Johanneke E. A. Portielje, Elisabeth M. P. Elsten, Albert‐Jan Ten Tije, Stefan Sleijfer, Agnes Jager
The Oncologist 2017; 22:901-909; first published on May 22, 2017; doi:10.1634/theoncologist.2016-0448

No front page content has been created yet.

 

The Oncologist and the Society for Translational Oncology (STO) partner with the Chinese Society of Clinical Oncology (中国抗癌协会临床肿瘤学协作专业委员会, CSCO) and the CSCO Foundation (中国临床肿瘤学会基金会) on educational initiatives that address critical health and cancer care issues in China. These efforts serve to foster communication between Chinese physicians and other leaders in oncology practice throughout the world.